SCHOTT Pharma’s products serve the growing market for injectable drugs
The ramp-up is expected to start in the course of 2024
More than 100 jobs will be created at the new site in Jagodina
Amid growing market demand, SCHOTT Pharma continues expanding its global manufacturing network and has decided to invest a double-digit million euro amount in a new production site for pharma drug containment solutions and delivery systems in Jagodina in central Serbia. "With this move, we are strengthening our presence in Europe, improving our competitiveness, and increasing our manufacturing flexibility to meet the needs of our customers in the region," explains Andreas Reisse, CEO of SCHOTT Pharma. The ramp-up for the manufacturing of ampoules for the pharmaceutical industry is expected to start in the course of 2024.
As a pioneer in pharma drug containment solutions and delivery systems, the company supplies the global pharma industry with high-quality solutions to safely store and administer medications. As such, the site in central Serbia, is intended to produce ampoules that are suitable for storing injectable drugs, e.g., painkillers, inflammation inhibitors, and anesthetics. Other product groups might follow based on market demand.
The production site in Jagodina, a town of 35,000 inhabitants and the administrative center of the Pomoravlje County, is well on schedule: the groundbreaking ceremony will take place at the end of December. In the first phase, SCHOTT Pharma will create 130 new jobs, and 350 are planned for the expansion phase.
09.01.2024, SCHOTT Pharma
此网站新闻材料的版权属于公司或第三方的新闻提供者，其所有权利保留。所有新闻材料对其访问者只能限于其本人使用，并且使用此材料的风险由其使用者独自自行承担。严禁对新闻材料进行再次发布和其它商业利用. 作为商业贸易的用途。如果新闻材料由第三方提供，当应用此新闻材料时，每个使用者都同意遵守，并且受此特定的项目的约束。Glass Global并不代表及认可新闻材料中所包含的内容及新闻中的外部网站的内容的准确性及可靠性。
Should the content or the design of these sites violate third parties rights or legal prescriptions, we kindly ask you to send us a respective message without invoice or cost. We guarantee that passages where the claim is considered as justified will be removed immediately, without any necessity to involve any lawyer into this issue. We will reject any claim caused by submission of a honorary note in this regard without any prior contact and confirmation of the issueby us and we reserve the right ssue counter claim ourselves because of violation of aforesaid conditions.